OakChart

Phathom Pharmaceuticals Inc

PHATHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

6.28+0.84 (15.34%)
2026-11-12 01:46 CET
Market cap
442.63 USD m
Revenue, TTM
274.88 USD m
Net income, TTM
-83.00 USD m
Free cash flow, TTM
-21.04 USD m
EPS diluted, TTM
-1.03
P/E
-
Compare

Price

PHAT against its 20, 50 and 200-day averages
2050200beatmiss
6.008.0010.0012.003.8M7.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PHATclose 6.2820-day 6.1750-day 7.09200-day 10.106.2852w low

65.7% under the 52-week high of 18.31 on 23 Dec 2025. 52-week low 5.02 on 23 Oct 2026. Last 15 sessions, 43.9% high to low

Volume 1.09× normal · the line is the 50-bar volume average

Profile

PHAT
52-week range, 10% of the way up
5.0118.31

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

IndexRUT
Employees371
IPOOct 25, 2019
Beta0.66
ATR, 14d0.55
Rel volume1.09
Short float17.88%
Insider own36.68%
Inst own60.30%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap510.51M
Enterprise Value881.40M
Income-83.00M
Sales274.88M
Book/sh-4.28
Cash/sh2.27
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees371
IPOOct 25, 2019

Ratios

P/E-
Forward P/E9.55
PEG-
P/S1.86
P/B-
P/C2.77
P/FCF-
EV/EBITDA-
EV/Sales3.21
Quick Ratio1.72
Current Ratio1.76
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.03
EPS next Y0.66
EPS next Q-0.07
EPS this Y75.58%
EPS next Y188.89%
EPS next 5Y-
EPS past 3/5Y15.64% 4.82%
Sales past 3/5Y- -
EPS Y/Y TTM72.98%
Sales Y/Y TTM86.75%
EPS Q/Q59.92%
Sales Q/Q71.14%
EarningsOct 29 BMO
EPS/Sales Surpr.-45.85% -0.12%

Ownership

Insider Own36.68%
Insider Trans0.00%
Inst Own60.30%
Inst Trans6.26%
ROA-28.36%
ROE-
ROIC-49.81%
Gross Margin80.68%
Oper. Margin-9.26%
Profit Margin-30.19%
SMA201.77%
SMA50-11.45%
SMA200-37.83%
Trades-

Technical

Shs Outstand81.22M
Shs Float51.48M
Short Float17.88%
Short Ratio6.38
Short Interest9.20M
52W High18.31 -65.70%
52W Low5.01 25.22%
Volatility8.08% 9.64%
ATR (14)0.55
RSI (14)49.52
Beta0.66
Rel Volume1.09
Avg Volume1.44M
Volume1,572,871

Performance

Perf Week10.56%
Perf Month-10.29%
Perf Quarter-31.59%
Perf Half Y-50.00%
Perf YTD-62.15%
Perf Year-56.27%
Perf 3Y-16.38%
Perf 5Y-71.45%
Perf 10Y-
Recom1.30
Target Price20.05
Prev Close5.45
Price6.28
Change %15.34%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 09, 2026InitiatedLLeerink PartnersMarket Perform$10+59.2%
Mar 27, 2026UpgradeBBarclaysEqual Weight → Overweight$18+186.6%
Dec 12, 2025InitiatedRRaymond JamesStrong Buy$28+345.9%
Dec 09, 2025InitiatedBBarclaysEqual Weight$16+154.8%
Feb 14, 2025InitiatedCCantor FitzgeraldOverweight$23+266.2%
May 03, 2024InitiatedSStifelBuy$24+282.2%
Jan 05, 2024ReiteratedNNeedhamBuy$23 → $26+314.0%
Aug 09, 2023InitiatedHH.C. WainwrightBuy$28+345.9%
May 11, 2023UpgradeEEvercore ISIIn-line → Outperform
Mar 13, 2023InitiatedCCraig HallumBuy$21+234.4%

Peers

Mkt cap
TickerCompanyMkt cap
ARDXArdelyx Inc786.79M
IRWDIronwood Pharmaceuticals Inc806.23M
RIGLRigel Pharmaceuticals838.31M
TAKTakeda Pharmaceutical Co ADR66.58B
BHCBausch Health Companies Inc3.13B
HRMYHarmony Biosciences Holdings Inc2.01B
COLLCollegium Pharmaceutical Inc770.99M
EOLSEvolus Inc491.11M
AQSTAquestive Therapeutics Inc449.96M
SUPNSupernus Inc6.12B

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Parikh AsitDirectorMay 20 '26Option Exercise4.9517,50086,62552,122May 21 05:16 PM
Parikh AsitDirectorJan 13 '26Option Exercise10.308,75090,125131,000Jan 15 04:45 PM
Parikh AsitDirectorDec 19 '25Option Exercise10.308,75090,125122,250Dec 23 05:00 PM
Basta Steven LPresident and CEONov 28 '25Option Exercise0.0090,0000131,625Dec 02 06:45 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
SURISimplify Propel Opportunities ETFAUM: 74.30M
IHEiShares U.S. Pharmaceuticals ETFAUM: 1.72B

News

latest 14 of 200
  • Phathom Pharmaceuticals to Participate in November Investor Conferences (GlobeNewswire)
  • Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA (vonoprazan) Tablets Exclusively at BlinkRx (GlobeNewswire)
  • Phathom Misses On A Decelerating Quarter As Cash-Flow Progress Collides With A New VOQUEZNA Exclusivity Overhang (Earnings Whispers)
  • Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Phathom Pharmaceuticals Provides Update on FDA Litigation (GlobeNewswire)
  • PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drugs Exclusivity (Stocktwits) -18.12%
  • Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA (GlobeNewswire)
  • Phathom's Prescribing Friction Faces Its First Test After Guidance Cut Rattled Investors (Earnings Whispers)
  • Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026 (GlobeNewswire)
  • Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA (vonoprazan) at ACG 2026 (GlobeNewswire)
  • Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting (GlobeNewswire)
  • Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA (vonoprazan) for As-Needed Treatment of Non-Erosive GERD (GlobeNewswire)
  • PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside CEO Plays Down Upcoming Rival (Stocktwits) -8.06%
  • Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-29-0.160-0.110-0.16084.7284.8210
2026Q22026-07-30-0.210-0.176-0.21074.2773.2310
2026Q12026-04-30-0.370-0.291-0.37058.3055.9010
2025Q42026-02-26-0.290-0.412-0.28757.5857.175
2025Q32025-10-30-0.410-0.463-0.40849.5046.998
2025Q22025-08-07-1.050-0.950-1.04639.5036.328
2025Q12025-05-01-1.310-1.103-1.31128.5229.028
2024Q42025-03-06-1.050-1.215-1.04829.6624.938
2024Q32024-11-07-1.320-1.469-1.32416.3512.617
2024Q22024-08-08-1.560-1.320-1.5627.325.687
2024Q12024-05-09-1.420-1.321-1.4191.911.636
2023Q42024-03-07-1.390-1.077-1.3890.680.407
2023Q32023-11-09-0.760-0.892-0.7620.000.007
2023Q22023-08-10-0.840-0.978-0.8450.000.007
2023Q12023-05-10-0.890-1.261-0.8930.000.006
2022Q42023-02-28-1.330-1.351-1.3330.000.006

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-22.437-8.505-10.3170.000.00
2020FY-3.880-3.407-3.8840.000.00
2021FY-3.890-3.967-3.8880.000.00
2022FY-5.050-5.028-5.0550.000.00
2023FY-3.930-3.723-3.9310.680.39
2024FY-5.290-5.294-5.29255.2550.50
2025FY-3.030-3.157-3.030175.11174.5
2026FY--0.740--315.03
2027FY-0.658--488.03
2028FY-1.988--669.35
2029FY-3.196--823.65
2030FY-4.140--944.01

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-2992397.7395.60101.15
2026Q4S2026-10-20101197.8294.38102.49
2026Q4S2026-10-16101098.2794.38102.49
2026Q4S2026-10-15101098.3494.38102.49
2026Q4S2026-10-13100098.1494.38102.49
2026Q4S2026-10-12100698.1494.38102.49
2026Q4S2026-09-08100998.1494.38102.49
2026Q4S2026-07-3090998.5595.66102.49
2026Q4S2026-07-29923106.0198.33113.2
2026Q4S2026-07-21940110.13105113.2
2026Q4S2026-07-16930109.06101.9113.2
2026Q4S2026-07-15920108.63101.9112.13
2026Q4S2026-07-14910108.48101.9111.1
2026Q4S2026-06-16924108.48101.9111.1

Estimate history

EPS, annual-0.053-10.317-3.884-3.888-5.055-3.931-5.292-3.034-1.0303
Period20182019202020212022202320242025TTM
EPS, quarterly-1.324-1.048-1.311-1.046-0.408-0.287-0.37-0.21-0.164
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000.68255.252175.11274.88
Period20182019202020212022202320242025TTM
Sales, quarterly16.35229.66428.51939.50349.50457.58458.30174.27484.722
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual24.52724.72828.51630.51141.46957.9768.51871.41981.223
Period20182019202020212022202320242025MRQ
Shares, quarterly68.32468.51869.63870.10471.04371.41979.44280.0781.223
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue274.88175.1155.250.680.000.000.000.000.00
Cost of Goods Sold Incl. D&A53.1122.607.970.740.620.520.300.010.00
Gross Profit221.77152.5147.28-0.06-0.62-0.52-0.30-0.010.00
Selling, General and Administrative Excl. Other247.23312.50324.75167.25171.82134.56125.3627.311.23
Research and Development31.8232.7834.0849.9071.4472.3498.1520.370.02
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-25.45-159.99-277.47-167.31-172.44-135.08-125.67-27.32-1.23
Interest Expense62.7168.1172.0141.9727.306.794.584.180.01
Unusual Expense0.000.000.000.000.000.00-0.10224.720.05
Net Income Before Taxes-83.00-221.25-334.33-201.59-197.72-143.88-129.07-255.13-1.29
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-83.00-221.25-334.33-201.59-197.72-143.88-129.07-255.13-1.29
Net Income From Continuing Operations-83.00-221.25-334.33-201.59-197.72-143.88-129.07-255.13-1.29
Net Income-83.00-221.25-334.33-201.59-197.72-143.88-129.07-255.13-1.29
EPS (Recurring)-0.98-3.03-5.29-3.93-5.05-3.89-3.89-3.96-0.05
EPS (Basic, Before Extraordinaries)-1.03-3.03-5.29-3.93-5.05-3.89-3.88-10.32-0.05
EPS (Diluted)-1.03-3.03-5.29-3.93-5.05-3.89-3.88-10.32-0.05
EBITDA-24.98-159.35-276.67-166.74-171.82-134.56-125.36-27.31-1.23
Non-Operating Income (Expense)5.176.8515.157.692.02-2.021.081.080.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense23.7828.7224.0545.0224.1316.815.840.41-
Price To Sales Ratio2.256.919.28686.61-----
Gross Margin80.6887.0985.57-8.80-----
Operating Margin-9.26-91.36-502.18-24,532.55-----
Net Margin-30.19-126.35-605.09-29,558.94-----
Shares Outstanding81.2271.4268.5257.9741.4730.5128.5224.7324.53
Market Capitalization442.63442.63555.22522.72466.99617.931,036.95763.76797.11

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue84.7274.2758.3057.5849.5039.5028.5229.66
Cost of Goods Sold Incl. D&A18.3715.1012.007.656.195.043.723.81
Gross Profit66.3659.1846.3049.9443.3134.4724.8025.85
Selling, General and Administrative Excl. Other66.4463.1461.7855.8658.5994.39103.6685.27
Research and Development8.747.817.777.497.039.089.188.58
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-0.09-3.96-15.48-5.93-15.27-59.92-78.86-59.42
Interest Expense15.3915.1015.8016.4216.1117.5218.0718.59
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-13.90-17.58-30.37-21.15-29.97-75.81-94.32-74.45
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-13.90-17.58-30.37-21.15-29.97-75.81-94.32-74.45
Net Income From Continuing Operations-13.90-17.58-30.37-21.15-29.97-75.81-94.32-74.45
Net Income-13.90-17.58-30.37-21.15-29.97-75.81-94.32-74.45
EPS (Recurring)-0.16-0.21-0.37-0.29-0.41-1.05-1.31-1.05
EPS (Basic, Before Extraordinaries)-0.16-0.21-0.37-0.29-0.41-1.05-1.31-1.05
EPS (Diluted)-0.16-0.21-0.37-0.29-0.41-1.05-1.31-1.05
EBITDA0.04-3.85-15.37-5.80-15.12-59.75-78.69-59.22
Non-Operating Income (Expense)1.571.490.911.201.411.632.623.56
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.926.715.535.619.308.275.546.69
Price To Sales Ratio2.253.794.456.995.876.095.5110.44
Gross Margin78.3279.6879.4286.7287.5087.2586.9487.14
Operating Margin-0.10-5.34-26.55-10.29-30.85-151.69-276.53-200.30
Net Margin-16.40-23.67-52.09-36.73-60.55-191.91-330.71-250.98
Shares Outstanding81.2280.0779.4471.4271.0470.1069.6468.52
Market Capitalization442.63865.35875.451,180.19835.01669.52436.62555.22

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments129.97297.26381.39155.38183.26287.50243.760.88
Short Term Receivables78.1338.801.640.000.000.000.000.00
Inventories5.523.211.210.000.000.000.000.00
Other Current Assets15.3520.8713.195.133.273.8711.840.02
Total Current Assets228.97360.13397.43160.51186.53291.37255.600.90
Net Property, Plant & Equipment3.672.093.623.492.563.361.400.00
Total Investments and Advances2.862.862.860.510.000.000.000.00
Intangible Assets-------0.00
Deferred Tax Assets0.660.15------
Other Assets23.6513.239.930.300.340.380.180.00
Total Assets259.80378.47413.84164.81189.43295.11257.180.90
Short Term Debt Incl. Current Port. of LT Debt27.9020.287.840.710.497.830.161.95
Accounts Payable4.9810.5112.6010.005.1516.780.700.06
Other Current Liabilities99.1654.9418.3415.5313.2830.912.890.18
Total Current Liabilities132.0485.7338.7826.2418.9255.523.752.19
Long Term Debt561.27534.67438.12213.3990.8541.1923.410.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.660.15------
Other Liabilities4.0011.509.700.007.504.122.060.00
Total Liabilities697.97632.05486.60239.62117.28100.8429.222.19
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity-438.17-253.58-72.76-74.8172.16194.27227.96-1.29
Total Shareholders Equity-438.17-253.58-72.76-74.8172.16194.27227.96-1.29
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity-438.17-253.58-72.76-74.8172.16194.27227.96-1.29
Total Liabilities & Stockholders Equity259.80378.47413.84164.81189.43295.11257.180.90
Book Value Per Share-6.14-3.70-1.26-1.802.366.819.22-0.05
Tangible Book Value Per Share-6.14-3.70-1.26-1.802.366.819.22-0.05
Full-Time Employees3714274521127755254
Price to Book Ratio-1.27-2.96-29.18-17.478.324.883.38-5.23
Return on Assets-69.33-84.39-69.68-111.63-59.39-46.74-197.71-
Return on Equity-----108.01-61.14-225.11-
Return on Invested Capital-179.72-118.94-55.18-142.69-88.27-54.81-101.50-
Quick Ratio1.694.1610.226.129.865.2568.200.41
Current Ratio1.734.2010.256.129.865.2568.200.41

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-83.00-221.25-334.33-201.59-197.72-143.88-129.07-255.13-1.29
Depreciation0.470.630.800.570.620.520.320.01-
Other Funds (Non Cash)49.5166.2282.0677.0845.1322.227.34228.130.05
Funds from Operations-33.01-154.40-251.47-123.94-151.97-121.14-121.41-26.99-1.24
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital12.28-12.38-15.30-13.645.44-27.4851.72-9.520.21
Cash from Operating Activities-20.74-166.78-266.77-137.58-146.53-148.62-69.69-36.51-1.02
Capital Expenditures-0.30-0.23-0.14-1.63-1.04-0.33-1.04-25.250.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.30-0.23-0.14-1.63-1.04-0.33-1.04-25.250.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock127.751.64123.37155.5924.601.9489.46191.470.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock127.751.64123.37155.5924.601.9489.46191.470.00
Proceedsfrom Stock Options121.970.00121.78155.4624.600.0089.46191.470.00
Issuance or Reduction of Debt, Net-55.800.0059.40211.9995.4542.7625.00113.171.90
Change in Long Term Debt-55.800.0059.40211.9995.4542.7625.0024.850.00
Issuance of Long Term Debt173.250.0059.40211.9995.4596.8925.0024.850.00
Reduction of Long Term Debt-229.050.000.000.000.00-54.120.000.000.00
Net Financing Active Other Cash Flow-1.51-1.930.000.000.000.000.000.000.00
Other Financing Activities Uses-1.51-1.930.000.000.000.000.000.000.00
Cash from Financing Activities70.44-0.29182.77367.58120.0444.71114.46304.651.90
Net Change in Cash49.40-167.29-84.13228.37-27.53-104.2443.73242.890.88
Free Cash Flow-21.04-167.00-266.90-139.21-147.57-148.94-70.73-36.64-1.02
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments184.56182.48180.90129.97135.16149.57
Short Term Receivables107.6097.4280.7278.1355.7951.26
Inventories7.637.716.515.523.613.43
Other Current Assets8.228.308.4415.3513.2314.62
Total Current Assets308.01295.92276.57228.97207.78218.88
Net Property, Plant & Equipment3.253.383.523.673.852.12
Total Investments and Advances2.862.862.862.862.862.86
Deferred Tax Assets---0.66--
Other Assets30.9024.9122.1623.6525.7926.37
Total Assets345.02327.07305.12259.80240.29250.22
Short Term Debt Incl. Current Port. of LT Debt41.1937.9533.6827.9024.9321.76
Accounts Payable11.115.366.374.981.074.01
Other Current Liabilities122.60110.4684.9999.1667.1166.05
Total Current Liabilities174.90153.78125.04132.0493.1291.82
Long Term Debt514.26514.07513.53561.27558.20552.73
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.66--
Other Liabilities3.503.503.504.0011.5011.50
Total Liabilities692.66671.35642.08697.97662.82656.05
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-347.64-344.27-336.95-438.17-422.53-405.83
Total Shareholders Equity-347.64-344.27-336.95-438.17-422.53-405.83
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-347.64-344.27-336.95-438.17-422.53-405.83
Total Liabilities & Stockholders Equity345.02327.07305.12259.80240.29250.22
Book Value Per Share-4.28-4.30-4.24-6.14-5.95-5.79
Tangible Book Value Per Share-4.28-4.30-4.24-6.14-5.95-5.79
Full-Time Employees---371--
Price to Book Ratio-1.27-2.56-1.81-2.79-2.03-1.97
Return on Assets-28.36-34.32-52.49-69.33-87.53-115.93
Return on Invested Capital-8.34-10.35-17.20-17.18-22.09-51.61
Quick Ratio1.721.872.161.692.192.35
Current Ratio1.761.922.211.732.232.38

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-13.90-17.58-30.37-21.15-29.97-75.81
Depreciation0.120.110.110.130.160.17
Other Funds (Non Cash)11.5612.9013.0711.9717.2618.86
Funds from Operations-2.21-4.56-17.19-9.05-12.56-56.78
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.052.631.544.05-1.56-5.95
Cash from Operating Activities1.84-1.93-15.65-5.00-14.12-62.73
Capital Expenditures-0.11-0.04-0.06-0.09-0.03-0.10
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.11-0.04-0.06-0.09-0.03-0.10
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.373.55122.561.260.290.08
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.373.55122.561.260.290.08
Proceedsfrom Stock Options0.000.00121.970.000.000.00
Issuance or Reduction of Debt, Net0.000.00-55.800.000.000.00
Change in Long Term Debt0.000.00-55.800.000.000.00
Issuance of Long Term Debt0.000.00173.250.000.000.00
Reduction of Long Term Debt0.000.00-229.050.000.000.00
Net Financing Active Other Cash Flow-0.020.00-0.13-1.36-0.560.00
Other Financing Activities Uses-0.020.00-0.13-1.36-0.560.00
Cash from Financing Activities0.353.5566.64-0.10-0.270.08
Net Change in Cash2.081.5850.93-5.18-14.41-62.75
Free Cash Flow1.73-1.97-15.71-5.09-14.14-62.83

Revenue breakdown

Consolidation, Policy2024: -48.00K 2025: 10.00K
VOQUEZNA Product2024: 55.30M 2025: 175.10M
United States2024: 55.25M 2025: 175.11M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3017.88%9.2M51.5M1.46M
2026-10-1519.10%9.8M51.2M1.37M
2026-09-3019.65%10.1M51.4M1.36M
2026-09-1519.75%10.2M51.4M1.31M
2026-08-3121.04%10.8M51.5M1.30M
2026-08-1423.10%11.8M51.0M1.32M
2026-07-3126.12%13.3M51.0M1.24M
2026-07-1524.10%12.1M50.3M1.26M
2026-06-3023.84%12.0M50.3M1.19M
2026-06-1519.63%11.2M56.9M1.21M
2026-05-2918.20%10.4M56.9M1.21M
2026-05-1518.11%10.3M56.8M1.23M
2026-04-3019.47%9.7M50.0M1.17M
2026-04-1519.23%9.5M49.4M1.06M
2026-03-3122.26%10.6M47.8M1.17M
2026-03-1324.39%11.7M47.8M1.14M
2026-02-2723.37%11.2M47.8M1.09M
2026-02-1324.68%11.7M47.5M1.03M
2026-01-3025.07%11.4M45.5M1.05M
2026-01-1523.15%10.5M45.5M1.04M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.501.505.505.1016.2961.000.000.949-0.0950.001
call5.000.104.801.1014.3296.001.000.894-0.1490.002
call7.500.005.000.101.3143381430.223-0.0220.003
call10.000.004.900.012.40092.000.000.145-0.0300.002
call12.500.004.900.153.1251,0590.000.121-0.0350.002
call15.000.001.000.053.6735550.000.108-0.0380.002
call17.500.000.500.304.11216.000.000.100-0.0400.002
call20.000.004.900.507.9421.000.000.349-0.1430.003
call22.500.004.900.008.2990.000.000.343-0.1480.003
call25.000.004.900.958.6091.000.000.337-0.1530.003
put2.500.004.900.010.00055.000.00-0.029-0.0700.001
put5.000.004.900.5514.79547.000.00-0.106-0.1490.002
put7.500.103.602.617.3051,4250.00-0.777-0.0210.003
put10.002.006.004.108.3400.000.00-0.855-0.0290.002
put12.504.508.504.509.2380.000.00-0.879-0.0330.002
put15.007.0011.000.009.9170.000.00-0.892-0.0360.002
put17.509.5013.500.0010.4610.000.00-0.900-0.0380.002
put20.0012.0016.000.0010.9120.000.00-0.905-0.0400.002
put22.5014.5018.500.0011.2980.000.00-0.909-0.0410.002
put25.0017.0021.000.0011.6340.000.00-0.913-0.0420.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13G/ASEC
2026-11-02SCHEDULE 13D/ASEC
2026-10-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-268-KCurrent report2026-10-26SEC
2026-10-238-KCurrent report2026-10-23SEC
2026-10-084Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-09-298-KCurrent report2026-09-29SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-07-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-308-KCurrent report2026-07-30SEC
2026-07-29SCHEDULE 13GSEC
2026-07-20SCHEDULE 13G/ASEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-14SEC
2026-06-238-KCurrent report2026-06-23SEC
2026-05-274Statement of changes in beneficial ownership of securities2026-05-22SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-218-KCurrent report2026-05-19SEC
2026-04-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-308-KCurrent report2026-04-30SEC
2026-04-07DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-07ARSAnnual report to security holders. 2025-12-31SEC
2026-04-07DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-19SEC
2026-03-27S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-11007.08K1

Institutional holders

Manager% owned
Frazier Life Sciences Management, L.P.15.63%
Medicxi Ventures Management9.23%
BlackRock, Inc.5.67%
Invesco Ltd.5.05%
Carlyle Group Inc.4.32%
MILLENNIUM MANAGEMENT LLC4.23%
WASATCH ADVISORS LP3.64%
VANGUARD CAPITAL MANAGEMENT LLC3.33%
GW&K Investment Management, LLC2.63%
FRANKLIN RESOURCES INC2.47%

Funds

Fund% owned
Invesco Global Fund2.94%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.52%
Strategic Advisers U.S. Total Stock Fund1.68%
iShares Russell 2000 ETF1.60%
Nomura Small Cap Growth Fund1.24%
Wasatch Small Cap Growth Fund1.04%
Franklin Small Cap Growth Fund1.04%
Wasatch Micro Cap Fund0.77%
VANGUARD EXTENDED MARKET INDEX FUND0.74%
Fidelity Small Cap Index Fund0.67%

OakChart. PHAT. Cached 15 minutes.